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A B S T R A C T
Background
Acute lung injury (ALI), and acute respiratory distress syndrome (ARDS), are syndromes of severe respiratory failure. Adults with ALI
or ARDS have high mortality and significant morbidity. Partial liquid ventilation (PLV) may be better (i.e., cause less lung damage) for
these patients than other forms of respiratory support. Uncontrolled studies in adults have shown improvement in gas exchange and
lung compliance with partial liquid ventilation.
Objectives
To assess whether partial liquid ventilation reduces morbidity and mortality in adults with ALI or ARDS.
Search strategy
We searched The Cochrane Central Register of Controlled Trials (CENTRAL), The Cochrane Library Issue 2, 2004; MEDLINE (1966
to May 2004); and CINAHL (1982 to May 2004); intensive care journals and conference proceedings; reference lists and unpublished
literature.
Selection criteria
Randomized controlled trials which compared partial liquid ventilation with other forms of ventilation, in adults (16 years old or
greater) with ALI or ARDS, reporting one or more of the following: mortality; duration of mechanical ventilation, respiratory support,
oxygen therapy, stay in the intensive care unit, or stay in hospital; infection; long term cognitive impairment or health related quality
of life; long term lung function; or cost.
Data collection and analysis
Two reviewers independently evaluated the quality of the relevant studies and extracted the data from the included studies.
Main results
Problems with the inadequacy of the primary report of the one included study do not allow us to report any quantitative results
for patients with ALI or ARDS. The only outcome we considered to be of clinical significance and reported for all enrolled patients
(i.e., patients with ALI and ARDS and less severe respiratory insufficiency) was 28 day mortality. There was no statistically significant
difference between groups for this outcome with a relative risk for 28 day mortality in the PLV group of 1.15 (95% confidence intervals
of 0.64 to 2.10).
Authors’ conclusions
There is no evidence from randomized controlled trials to support or refute the use of partial liquid ventilation in adults with ALI or
ARDS; adequately powered, high quality randomized controlled trials are still needed to assess its efficacy. Clinically relevant outcome
measures should be assessed (especially mortality at discharge and later, duration of respiratory support and hospital stay, and long term
cognitive and quality of life outcomes) and the studies should be published in full.
1Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome
(Review)
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
P L A I N L A N G U A G E S U M M A R Y
There is no evidence from randomized controlled trials to support or refute the use of partial liquid ventilation in adults with severe
lung disease.
Severely ill adults can get severe lung disease that stops enough oxygen getting into the blood: this is called acute lung injury or acute
respiratory distress syndrome. About half of these patients die. To try and improve the situation a special liquid (perfluorocarbon) is
introduced into the lungs to partly replace the gas in normally gas-filled lungs: this is called partial liquid ventilation (PLV). PLV allows
the use of lower pressures and volumes delivered by the mechanical ventilator: increasing the amount of oxygen in the blood whilst
causing less damage to the lung. Only one trial has been reported on PLV in adults and this does not provide enough evidence to
support its use.
B A C K G R O U N D
Acute lung injury (ALI), and the more severe subset acute respira-
tory distress syndrome (ARDS), are syndromes of severe respira-
tory failure characterized by acute onset, severe hypoxaemia and
bilateral chest infiltrates on chest x-ray (CXR), without evidence
of left heart failure. ARDS was first described by Ashbaugh in
1967 (Ashbaugh 1967). The causes of ALI or ARDS are many and
they may result from primary lung disease (pneumonia, aspiration
or inhalation injury, lung trauma, fat emboli, near-drowning) or
extra-pulmonary causes (septicaemia, trauma and shock, cardio-
pulmonary bypass, drug overdose, acute pancreatitis, transfusion)
(Ware 2000).
ALI or ARDS results in mismatch between ventilation and perfu-
sion (V/Q mismatch), with well ventilated but poorly perfused ar-
eas in the lung and well perfused but poorly ventilated areas, lead-
ing to severe hypoxaemia. They are also characterized by severe het-
erogenous atelectasis (differing degrees of collapse throughout the
lung) and decreased lung compliance (decreased ease with which
the lung expands). Hence, patients with ALI or ARDS universally
require respiratory support and the mainstay of treatment is endo-
tracheal intubation and mechanical ventilation (Tobin 2001). The
syndromes are also characterized by a prominent pulmonary and
systemic inflammatory response. There is loss of integrity of the
alveolar-capillary barrier in the lung with increased inflammatory
cell and oxygen free radical mediated injury and increased pul-
monary and systemic pro-inflammatory cytokines (Ware 2000).
Mechanical ventilation for ALI or ARDS may cause physical dam-
age to the lungs, with the use of high pressures (barotrauma) and
large tidal volumes (volutrauma), causing ventilator-induced lung
injury (VILI) and its secondary inflammatory effects. Decreasing
baro- and volu-trauma may lower mortality and morbidity (Tobin
2001; van der Werf 2001).
Generally accepted mortality figures for ALI or ARDS have ranged
from 40 to 60% (Ware 2000); although recent studies have shown
decreasing mortality (Abel 1998; Milberg 1995). Mortality in this
condition is often due to the primary disease process, especially
septicaemia, or the associated multi-organ dysfunction rather than
respiratory failure per se (Monchi 1998; Ware 2000; Zilberberg
1998) and therefore may not be amenable to alterations in ven-
tilatory techniques. However more recent studies show a lower
mortality with ’protective’ ventilatory strategies and,or, an ’open-
lung’ approach (i.e., maximising lung recruitment and functional
residual capacity) in adults with ARDS, suggesting that VILI does
have a role in increasing mortality; and that decreasing baro- and
volu-trauma may lead to improved survival (Abel 1998; Amato
1998; ARDS Network 2000; Baudouin 2001; Tobin 2001, van
der Werf 2001). A recent Cochrane review (Petrucci 2004) con-
cluded that mechanical ventilation with lower tidal volumes in
adults with ALI or ARDS reduced mortality. Mortality and other
outcomes have been shown to vary by the age of the patient, the
initial severity of the ALI or ARDS or patients condition (e.g. by
APACHE score) and by the underlying cause of the ALI or ARDS
(Monchi 1998; Suntharalingam 2001; Ware 2000)
There is also substantial short and long term morbidity associated
with these syndromes. Short term morbidity leads to prolonged
ventilator dependence and prolonged stay in intensive care units
(ICU) and hospital. Long term morbidity includes decreased lung
function, decreased health related quality of life, cognitive impair-
ments, and high rates of disability and un-employment (Rothen-
hausler 2001; Schelling 2000).
The mainstay of treatment of ALI and ARDS is mechanical ven-
tilation. Many forms of additional therapies have been consid-
ered and some of these subjected to randomized controlled tri-
als. Adjuncts to mechanical ventilation have included: extracorpo-
real life support (ECLS), inhaled nitric oxide, endogenous surfac-
tant, prone positioning, high frequency ventilation and a variety
of pharmaceutical therapies (anti-inflammatory medication, an-
tioxidants, anticytokine agents, prostaglandins) (Conner 2000).
The ventilatory techniques that seem to improve outcomes in ALI
or ARDS are the ’lung-protective’ strategies that aim to decrease
VILI (Brower 2000; van der Werf 2001).
Partial liquid ventilation (PLV) has been proposed as a less inju-
rious form of respiratory support for patients with severe respira-
tory failure, ALI and ARDS. In 1991 Fuhrman et al (Fuhrman
1991) introduced the technique of using functional residual ca-
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pacity (FRC) volumes of perfluorocarbon liquid (PFC) with con-
ventional gas ventilation; they called it perfluorocarbon associated
gas exchange (PAGE). This technique has become known as PLV
and it is this technique of liquid assisted ventilation which has the
most promise for practical clinical application in intensive care.
Various models of acute lung injury have shown the benefits of
using PLV compared with conventional mechanical ventilation
alone. Many animal studies have shown that PLV improves oxy-
genation, CO2 removal and lung compliance, and leads to less
lung damage and VILI (Davies 1999; Wiedemann 2000). All of
these benefits can be achieved whilst using lower ventilatory pres-
sures and smaller tidal volumes (Davies 1999; Wiedemann 2000).
PLV also gives superior alveolar recruitment in the dependent ar-
eas of the lung and redistributes pulmonary blood flow to improve
V/Q matching and decrease intra-pulmonary shunting (Davies
1999; Wiedemann 2000). PFCs have also been demonstrated to
have significant anti-inflammatory effects in both in vivo animal
models of ALI and in vitro cell cultures (Wiedemann 2000). PFCs
can decrease inflammatory cytokine release and oxygen free rad-
ical production by alveolar macrophages and decrease neutrophil
activation and chemotaxis (Wiedemann 2000). Patients ventilated
for ALI and ARDS are usually sedated; this would be no different
for patients ventilated with PLV.
Case series’ reports of the use of PLV in adults with ALI or ARDS
(with no control group) have shown improvement in oxygenation
and lung compliance in patients also on ECLS (Hirschl 1996), and
improved gas exchange with haemodynamic stability and minimal
adverse side effects in patients ventilated with PLV alone (Hirschl
1998). The optimal dose of PFC to use during PLV is unknown
and its beneficial effects may be apparent at lower doses of PFC
than the usual method where the initial dose of PFC is equivalent
to the functional residual capacity (approximately 30ml/kg). Vari-
ations in the technique of PLV may also include giving an initial
dose of PFC with or without further top-up doses to maintain
partial filling of the lungs (Davies 1999).
A recent Cochrane review (Davies 2004) found no evidence from
RCTs to support or refute the use of PLV in children with ALI or
ARDS.
O B J E C T I V E S
The primary objective was to assess whether partial liquid ventila-
tion reduces morbidity and mortality in adults with ALI or ARDS.
Sub-group analyses were planned to determine whether the results
differ by:
Population:
i. age;
ii. severity of: a) overall illness (e.g. APACHE or SAPS score), or
b) of ALI or ARDS;
iii. aetiology of ALI or ARDS (e.g. septicaemia, pneumonia,
trauma, burns, etc).
Mortality and other outcomes have been shown to vary by the age
of the patient, the initial severity of the ALI or ARDS or patients
condition (e.g. by APACHE score) and by the underlying cause
of the ALI or ARDS (Monchi 1998; Suntharalingam 2001; Ware
2000).
Intervention:
i. initial amount or dose of PFC;
ii. whether continuous PLV or intermittent doses of PFC;
iii. type of PFC (e.g. perflubron, Rimar, etc).
The correct dose of PFC to use when initiating PLV is unknown.
Variations in the technique of PLV may also include giving an ini-
tial dose of PFC with or without further top-up doses to maintain
partial filling of the lungs. Various types of PFC with different
physical and chemical properties may be used. (Davies 1999).
The use of co-interventions in addition to PLV:
i. use of inhaled nitric oxide;
ii. use of surfactant;
iii. use of the prone position;
iv. high frequency ventilation.
Whilst the mainstay of treatment of ALI or ARDS is mechanical
ventilation, additional therapies have been considered and some of
these subjected to randomized controlled trials. Adjuncts to me-
chanical ventilation have included: inhaled nitric oxide, endoge-
nous surfactant, prone positioning, and high frequency ventila-
tion (Conner 2000); all can be used in conjunction with PLV.
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
Randomized controlled trials (RCTs) of adequate quality - at least
two of the following criteria (each rated as either adequate, un-
clear or inadequate) must be rated as adequate for the study to be
included in the review:
1. allocation concealment (blinding of randomization);
2. blinding of intervention,
3. completeness of follow up and;
4. blinding of outcome measurement.
Cross-over studies will be excluded.
Types of participants
Adults, (aged 16 years old or greater), with ALI or ARDS from any
cause who are intubated and are being supported by a mechanical
ventilator.
Definition of ALI (Bernard 1994):
1. acute onset respiratory failure;
2. bilateral opacities on CXR consistent with pulmonary oedema;
3. pulmonary artery wedge pressure <18mmHg or no clinical ev-
idence of raised left atrial pressure;
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4. PaO2/FiO2ratio <=300mmHg.
Definition of ARDS (Bernard 1994):
1. acute onset respiratory failure;
2. bilateral opacities on CXR consistent with pulmonary oedema;
3. pulmonary artery wedge pressure <18mmHg or no clinical ev-
idence of raised left atrial pressure;
4. PaO2/FiO2 ratio <=200mmHg.
Types of intervention
Partial liquid ventilation compared with other forms of ventilatory
management without the use of perfluorocarbon liquids or vapour.
Types of outcome measures
One or more of the following outcomes must be reported:
Primary:
• Mortality (28 day, at discharge from ICU, at discharge from
hospital, and at 1, 2, and 5 years).
Secondary:
• duration of mechanical ventilation;
• duration of respiratory support;
• duration of oxygen therapy;
• duration of stay in the ICU;
• duration of stay in hospital;
• infection (septicaemia, pneumonia);
• long term cognitive impairment;
• long term health related quality of life;
• long term lung function;
• Cost.
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Anaesthesia Group methods used in reviews.
We searched The Cochrane Central Register of Controlled Trials
(CENTRAL), The Cochrane Library, Issue 2, 2004; MEDLINE
(1966 to May 2004); and CINAHL (1982 to May 2004).
RCTs of PLV in ALI or ARDS were identified from MEDLINE
using the MeSH heading ’RESPIRATORY DISTRESS SYN-
DROME, ADULT’ or the textwords ’ARDS’, ’ALI’ or ’acute lung
injury’ and the MeSH heading ’FLUOROCARBONS’ or the
textword ’partial liquid ventilation’.
The MEDLINE search will be found in the ’Additional tables
(Table 01).
Other databases, including CINAHL and the Cochrane Central
Register of Controlled Trials (CENTRAL) were searched using a
similar strategy. Bibliographies of published trials and conference
proceedings were also reviewed.
No language restrictions were applied.
We also attempted to identify unpublished trials by contacting
experts in the field of PLV research.
M E T H O D S O F T H E R E V I E W
The standard methods of the Cochrane Collaboration and its
Anaesthesia Review Group were used. The two reviewers worked
independently to search for and assess trials for inclusion and
methodological quality. Differences were resolved by discussion
and consensus of the reviewers.
Studies were assessed using the following key criteria:
1. allocation concealment (blinding of randomization);
2. blinding of intervention;
3. completeness of follow up, and;
4. blinding of outcome measurement.
Each were rated as either adequate, unclear or inadequate. At least
two criteria must have been rated as adequate for the study to be
included in the review.
Data were extracted independently by the reviewers. Differences
were resolved by discussion and consensus of the reviewers. Inves-
tigators were contacted for additional information or data where
appropriate.
It was planned that if sufficient studies had been identified and
included in this review we would perform a sensitivity analysis
based on the methodological quality of the studies.
For individual trials, where possible, mean differences (and 95%
confidence intervals) were to be reported for continuous variables
such as duration of oxygen therapy. For categorical outcomes such
as mortality, the relative risk and risk difference (and 95% confi-
dence intervals) were to be reported.
For the meta-analysis, where possible, weighted mean differences
(and 95% confidence intervals) were to be reported for continu-
ous variables, and the relative risk and risk difference (and 95%
confidence intervals) were to be reported for categorical outcomes.
A random effects model was to be used.
D E S C R I P T I O N O F S T U D I E S
195 titles and abstracts were found using this search strategy. Of
these 195 papers, ten were reviewed in full. Three reports of studies
(Alliance 2002; Hirschl 2002; Schuster 2001) were identified as
potentially meeting the inclusion criteria for this review.
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The most recent study has not been published and the preliminary
results have only been announced in a press release from Alliance
Pharmaceutical Corporation: a “phase 2-3 clinical study that eval-
uated the use of Partial Liquid VentilationTM (PLV) with LiquiV-
ent® for adult patients with Acute Respiratory Distress Syndrome
(ARDS) being supported by a mechanical ventilator” (Alliance
2002). The study investigators mentioned in the press release have
been contacted but no further information about the trial or data
from it have been made available. The press release noted that:
“Efficacy data from the study revealed that PLV with LiquiVent
did not meet either the primary study endpoint for improvement
in ”ventilator free days“ or the secondary endpoint of improve-
ment in 28-day mortality”.
Schuster et al (Schuster 2001) reported on a post hoc analysis of 16
patients from another trial (as yet, not published) examining the
radiographic appearances during treatment with PLV with either
high or low dose PFC. The study design was randomized (to high
or low volume PFC: randomization method is not stated). The
primary end point was the CXR homogeneity of PFC filling over a
48 hour period and secondary end points included oxygenation as
a function of CXR appearance. Oxygenation was reported as better
at 24 hours (p<0.05) with homogenous filling. It is unclear from
the report (and no further information is available after contacting
the study investigators) if there were other patients in the larger
study (i.e., were there other patients in the study that received
either low or high dose PFC and, if there were, were these 16
the only patients reported because they were the only ones who
had the appropriate x-rays?). It is therefore unknown how many
patients were randomized to either treatment group.
Therefore, only one study was identified and found eligible for
inclusion in this review (Hirschl 2002) (see Table: ’Characteris-
tics of Included Studies’). This was a prospective multi-centre ran-
domized controlled trial done in 18 centres between July 1995
and August 1996. Each study centre enrolled an average of only
five patients into the study (90 patients in 18 centres, only four
sites enrolled more than five patients and those four sites overall
enrolled 52 of the 90 patients); many of these centres would only
have enrolled one or two patients into the study and many would
have only treated one patient with PLV. This may have led to
wide variation in the application of PLV, the success of which may
well be determined in part by how the PLV is applied. Initially
patients who developed ALI or ARDS (who met the criteria of
ARDS for less than 24 hours prior) were randomized to receive
PLV or conventional ventilation for a maximum of five days. Pa-
tients with multiple organ failure were excluded. The entry cri-
teria changed a number of times during the study: in particular
after the enrolment of 45 subjects the entry criteria were changed
such that patients with respiratory failure that was less severe than
ALI or ARDS were enrolled. The initial primary outcome was
oxygenation, but this was changed during the study to the num-
ber of ventilator free days. Secondary outcomes included 28 day
mortality, PaO2/FiO2 ratio and A-a gradient. It is not clear why
more clinically important outcomes (see ’Criteria for considering
studies for this review: Types of outcome measures’ above) were
not reported. A large number of post hoc analyses were reported.
It is unknown whether the analysis is based on an intention to
treat. We have contacted the first author of this study and the
company that sponsored it and no further information or data are
forthcoming from either source.
M E T H O D O L O G I C A L Q U A L I T Y
In Hirschl et al’s study (Hirschl 2002):
1.treatment allocation was randomized (exact method not stated);
2.group allocation was concealed - “a central office at Alliance
Pharmaceutical was contacted for group assignment...”;
3.treatment was not blinded;
4.follow-up was assumed to be complete for the unambiguous
outcome of 28 day mortality;
5.whether the published outcomes were assessed by blinded eval-
uators is unknown (blinding of the assessment of death is not ap-
plicable).
R E S U L T S
Problems with the inadequacy of the primary report of the one
included study (Hirschl 2002) do not allow us to report any quan-
titative results. This is because some of the patients enrolled in the
trial did not have ALI or ARDS and the exact numbers of patients
that met the criteria for ALI or ARDS are not stated nor are the
exact numbers given for each outcome for these subgroups of pa-
tients. This trial also reports a large number of post hoc analyses
that have not been considered in this review: they should be inter-
preted with great caution (see notes in ’Characteristics of included
studies’).
The only outcome, that we considered to be of clinical signifi-
cance, reported for all enrolled patients (i.e., patients with ALI
and ARDS and less severe respiratory insufficiency) was 28 day
mortality. Although not reported we assumed 100% follow-up for
analysis of this short-term outcome. There was no statistically sig-
nificant difference between groups for this outcome with a relative
risk for 28 day mortality in the PLV group of 1.15 (95% confi-
dence intervals of 0.64 to 2.10). None of the following outcomes
were reported: mortality at any time after day 28, duration of me-
chanical ventilation, duration of respiratory support, duration of
oxygen therapy, duration of stay in the intensive care unit, dura-
tion of stay in hospital, infection, long term cognitive impairment,
long term health related quality of life, long term lung function,
cost.
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D I S C U S S I O N
While it has been suggested that PLV is a promising alternative
mode of mechanical ventilation for adults with ALI or ARDS,
there are no data from adequately powered RCTs available to de-
termine whether PLV is effective or not in decreasing morbidity or
mortality. The wide confidence intervals for 28 day mortality seen
in the study by Hirschl et al (Hirschl 2002) mean that a clinically
significant difference in either direction cannot be excluded.
It is unfortunate that the only RCT investigating PLV in adults
with ALI or ARDS reported so far (Hirschl 2002) has little data on
clinically relevant outcomes (especially, mortality at discharge and
later; duration of respiratory support and hospital stay; and long
term outcomes). It is also unfortunate that the study entry criteria
were changed to allow patients with less severe respiratory insuf-
ficiency to be enrolled in the study without reporting the exact
numbers of patients that met the original study entry criteria (i.e.,
ALI or ARDS). The limited information available on complete-
ness of follow-up or blinding of outcome assessment also makes
it difficult to make a complete assessment of study quality. No
further information is forthcoming from the study investigators
or the company that sponsored the trial.
It is also unfortunate that the latest RCT (Alliance 2002) has not
been published and that no data are forthcoming from the study
investigators or the company that sponsored the trial.
The under-reporting of RCTs due to publication bias has been
well described (Dickersin 1987; Dickersin 1990; Dickersin 1993).
In a systematic review of pharmaceutical industry sponsorship and
research outcome Lexchin et al (Lexchin 2003) found that research
funded by drug companies was less likely to be published. Some
consider the selection of reports for publication on the basis of
“positive results”, or the failure of investigators to publish results
with sufficient detail to allow judgments to be made about their
validity as scientific misconduct (Chalmers 1990). It is unknown
whether any of these factors are operating here.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no evidence from RCTs to support or refute the use of
PLV in adults with ALI or ARDS.
Implications for research
If adults with ALI or ARDS are to be treated with PLV then
adequately powered, high quality RCTs are still needed to assess its
efficacy. Clinically relevant outcome measures should be assessed
(especially, mortality at discharge and later; duration of respiratory
support and hospital stay; and long term cognitive and quality of
life outcomes) and the studies should be published in full.
P O T E N T I A L C O N F L I C T O F
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T A B L E S
Characteristics of included studies
Study Hirschl 2002
Methods Prospective, multi-centre, randomized controlled trial.
Done between July 1995 and August 1996.
Participants Ninety patients with ALI/ARDS.
Entry criteria:
bilateral infiltrates on CXR for <=5 days,
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Characteristics of included studies (Continued )
ventilated for <=5 days,
FiO2>=0.5,
PaO2/FiO2 ratio >60 and <300,
aged 15 - 75 years.
The first 45 patients were stratified according to Murray lung Injury score - <=2.5 or >2.5. They had their
PaO2/FiO2 ratios determined at an FiO2 of 1.
The second 45 patients also had to have an APACHE 2 score of <30. They had their PaO2/FiO2 ratios
determined at an FiO2 of >=0.5.
Exclusion criteria:
1. On ventilator support for diagnosed ALI/ARDS or with FiO2 >0.4 for more than 24 h.
2. On ventilator support for reasons other than diagnosed ALI/ARDS for more than 3 d in the previous 21
d.
3. Tidal volume <4 ml/kg.
4. Neuromuscular respiratory failure or cardiac disease (Ppc, we >18 mmHg or clinical signs of left atrial
hypertension) causing the compromise in gas exchange.
5. Lung parenchymal or airway surgery within 30 d of screening.
6. Status asthmaticus or severe asthma currently under treatment with acute doses of systemic corticosteroids,
or
severe chronic obstructive pulmonary disease requiring chronic oxygen therapy.
7. Systolic blood pressure <90 mmHg, which cannot be adequately maintained with intravenous fluids and
high-dose pressors.
8. Intubation primarily for chronic interstitial lung disease (e.g., sarcoidosis, idiopathic pulmonary fibrosis).
9. Any active air leak from the lung into the pleural space.
10. Seizures refractory to anticonvulsant therapy.
11. High risk of mortality within 3 mo of screening for reasons other than ALI or ARDS or associated
complications (e.g., terminal cancer with a high short-term risk of mortality).
12. Hypersensitivity to perfluorocarbons.
13. Pregnant females.
14. Receipt of any other experimental drug within 30 d of screening.
15. Significant renal dysfunction defined by (1) serum creatinine greater than 3.0 mg/dl or (2) an increase
in serum creatinine of 0.8 mg/dl in 24 h.
16. Significant hepatic dysfunction defined by serum total bilirubin greater than 2.0 mg/dl and albumin less
than
2.5 g/dl; or a prothrombin time 3 s greater than control or >1.5 times the upper limit of normal and an
activated partial thromboplastin time >1.5 times the upper limit of normal.
17. Significant haematologic dysfunction defined by platelet count <75,000/mm3; a total white blood cell
count <1,000/ul; or evidence of disseminated intravascular coagulation.
18. In patients 46-90, high risk of mortality as defined by an APACHE II score >=30.
Interventions Randomized to receive: partial liquid ventilation (PLV), or conventional ventilation (CMV) for a maximum
of four days for the first 45 patients and a maximum of five days for subsequent patients. Groups were
allocated at a PLV to CMV ratio of 2:1.
Outcomes The initial primary outcome was oxygenation, but this was changed during the study to mean no. of ventilator
free days to day 28. Secondary outcomes included 28 day mortality, PaO2/FiO2 ratio, A-a gradient, and
lung mechanics.
The study showed that there was no difference in:
1. No. of ventilator free days (p = 0.85),
2. Mortality at day 28 (p = 0.63),
3. Any pulmonary related parameters.
Ventilator free days to day 28 is defined as “On Day 28, each survivor received 1 point for every day
following discontinuation of mechanical ventilation, including the day of extubation, if the patient remained
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successfully weaned for the remainder of the day. Patients who died during the first 28 days of the study
received a VFD score of zero. Patients who were reintubated had days counted toward a VFD only if they
remained off the ventilator for the remainder of the 28-day period. For instance, if a patient was extubated
for two days and then reintubated for the remainder of the 28 days, the VFD was zero. Only those days
for which the patient was extubated and remained extubated for the remainder of the 28-day experimental
period counted toward VFD.”
The following outcomes which we considered clinically relevant were not reported:
Mortality (at discharge from ICU, at discharge from hospital, and at 1, 2, and 5 years)
Duration of mechanical ventilation
Duration of respiratory support
Duration of oxygen therapy
Duration of stay in the intensive care unit
Duration of stay in hospital
Infection (septicaemia, pneumonia)
Long term cognitive impairment
Long term health related quality of life
Long term lung function
Cost
Notes A large number of post hoc analyses are also reported.
Post hoc analyses showed a more rapid discontinuation of ventilation in the PLV arm (p = 0.045) though
patients who were randomized to PLV had a longer length of CMV prior to randomization (p = 0.12). Thus,
a beta error may be present, as the lag time involved may explain the difference in rapidity of discontinuation.
There was also a trend towards increase in VFD in those patients under 55 (p = 0.06).
18 centres were involved, though only 4 centres enrolled more than 5 patients of the total 90 patients.
It is not clear whether the data are analysed by ’intention-to- treat.’
There are a number of concerns with this study: the large number of changes in admission criteria; the
change in primary end points; the duration of the study period; the exclusion criteria, excluding patients with
multiple organ failure seems to limit generalizability as most patients die with ARDS rather than because of
it.
Allocation concealment A
A-a - alveolar-arterial,
ALI - acute lung injury,
APACHE - acute physiology and chronic health evaluation system,
ARDS - acute respiratory distress syndrome,
CMV - conventional mechanical ventilation
CXR - chest x-ray,
d - days
FiO2 - fraction of inspired oxygen
h - hours
ICU - intensive care unit
mo - months
PaO2 - arterial oxygen tension,
PFC - perfluorocarbon liquid,
PLV - partial liquid ventilation,
Ppc,we - pulmonary capillary wedge pressure
s - seconds,
VFD - ventilator free days.
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Characteristics of excluded studies
Hirschl 1995 Case series
Not randomized
No control group
Hirschl 1996 Not randomized
No control group
Hirschl 1998 Not randomized
No control group
Kazerooni 1996 Not randomized
No control group
Meaney 1997 Case series
Not randomized
No control group
Reickert 2001 Not randomized
No control group
Schuster 2001 This RCT involved the post hoc analysis of 16 patients from another trial (as yet, not published). It is unclear from
the paper (and there was no further information available after contacting the study investigators) if there were other
patients in the larger study. That is, were there other patients in the study that received either 10 or 20 ml/kg of
perflubron but these 16 were the only ones reported because they were the only ones who had the appropriate x-
rays?
RCT - randomized controlled trial.
A D D I T I O N A L T A B L E S
Table 01. MEDLINE search
PLV search
1 exp RESPIRATORY DISTRESS SYNDROME, ADULT/
2 ALI.mp. [mp=title, original title, abstract, name of substance, mesh subject heading]
3 ARDS.mp. [mp=title, original title, abstract, name of substance, mesh subject heading]
4 acute lung injury.mp. [mp=title, original title, abstract, name of substance, mesh subject heading]
5 exp FLUOROCARBONS/
6 partial liquid ventilation.mp. [mp=title, original title, abstract, name of substance, mesh subject heading]
7 (1 or 2 or 3 or 4) and (5 or 6)
A N A L Y S E S
Comparison 01. Partial liquid ventilation (PLV) versus conventional mechanical ventilation (CMV)
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 28 day mortality Relative Risk (Random) 95% CI Subtotals only
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adult; Liquid Ventilation [∗methods]; Morbidity; Randomized Controlled Trials; Respiratory Distress Syndrome, Adult [mortality;
∗therapy]
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MeSH check words
Humans
C O V E R S H E E T
Title Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury
and acute respiratory distress syndrome
Authors Davies MW, Fraser JF
Contribution of author(s) MWD - conceived the question, wrote the protocol, searched for studies, assessed all po-
tential studies for inclusion, extracted data, analysed the results and wrote the review.
JFF - co-wrote protocol, searched for studies, assessed all potential studies for inclusion,
extracted data, analysed the results and co-wrote the review.
Issue protocol first published 2002/3
Review first published 2004/4
Date of most recent amendment 26 April 2005
Date of most recent
SUBSTANTIVE amendment
25 August 2004
What’s New Information not supplied by author
Date new studies sought but
none found
Information not supplied by author
Date new studies found but not
yet included/excluded
Information not supplied by author
Date new studies found and
included/excluded
Information not supplied by author
Date authors’ conclusions
section amended
Information not supplied by author
Contact address Dr Mark William Davies
Staff Neonatologist
Grantley Stable Neonatal Unit
Royal Women’s Hospital
Butterfield St
Herston
Brisbane
Queensland
4029
AUSTRALIA
E-mail: Mark_Davies@health.qld.gov.au
Tel: +61 7 3636 2245
Fax: +61 7 3636 5259
DOI 10.1002/14651858.CD003707.pub2
Cochrane Library number CD003707
Editorial group Cochrane Anaesthesia Group
Editorial group code HM-ANAESTH
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G R A P H S A N D O T H E R T A B L E S
Analysis 01.01. Comparison 01 Partial liquid ventilation (PLV) versus conventional mechanical ventilation
(CMV), Outcome 01 28 day mortality
Review: Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome
Comparison: 01 Partial liquid ventilation (PLV) versus conventional mechanical ventilation (CMV)
Outcome: 01 28 day mortality
Study PLV CMV Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Hirschl 2002 27/65 9/25 100.0 1.15 [ 0.64, 2.10 ]
Subtotal (95% CI) 65 25 100.0 1.15 [ 0.64, 2.10 ]
Total events: 27 (PLV), 9 (CMV)
Test for heterogeneity: not applicable
Test for overall effect z=0.47 p=0.6
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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